Budget impact analysis of antiplatelet therapy with cangrelor in patients with acute coronary artery disease undergoing percutaneous coronary intervention in Belgium
Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Ferrer, Barcelona, Spain Background Cangrelor is a novel, intravenous, potent, fast onset, direct-acting, P2Y12 receptor antagonist that blocks adenosine diphosphate-induced platelet activation and aggregation with a half-life of 3-6 min. Co-administered with acetylsalicylic acid, it is indicated for reducing thrombotic cardiovascular events in patients with coronary artery disease (CAD) (ST-elevation myocardial infarction (STEMI), non-STEMI, stable CAD) undergoing percutaneous coronary interven... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Reihe/Periodikum: | European Heart Journal. Acute Cardiovascular Care ; volume 10, issue Supplement_1 ; ISSN 2048-8726 2048-8734 |
Verlag/Hrsg.: |
Oxford University Press (OUP)
|
Schlagwörter: | Cardiology and Cardiovascular Medicine / Critical Care and Intensive Care Medicine / General Medicine |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27373951 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1093/ehjacc/zuab020.106 |